GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Future 3-5Y EPS without NRI Growth Rate

SDZNY (Sandoz Group AG) Future 3-5Y EPS without NRI Growth Rate : 15.64 (As of Mar. 26, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate is 15.64.

Competitive Comparison of Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate falls into.


Sandoz Group AG  (OTCPK:SDZNY) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Sandoz Group AG Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XSWX:GALD XSWX:SFZN XSWX:PPGN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA NSE:DIVISLAB HKSE:03692 SZSE:000538 BOM:500087 ITCI VTRS TSE:4507 NBIX NSE:TORNTPHARM SHSE:688506
Traded in Other Exchanges
SDZXF:USA SDZz:UK 0SAN:UK D8Y0:Germany SDZ:Switzerland
Address
Centralbahnstrasse 4, Basel, CHE, 4051
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.